艾柯医疗携神经介入创新成果亮相中关村论坛

Group 1 - The core viewpoint of the news is that Aiko Medical showcased its innovative products in the neurointervention field at the 2025 Zhongguancun Forum, highlighting its advancements and contributions to the industry [1][2]. - Aiko Medical's Lattice flow-directed stent is noted for its wide application in treating small to medium-sized vertebral artery aneurysms, being the product with the largest approved indication range in its category [1][2]. - The Lattice stent utilizes cobalt-chromium alloy and features world-first technologies such as a mechanical balloon delivery system and MIROR surface modification, significantly reducing surgical difficulty and time while improving patient cure rates and safety [1][2]. Group 2 - Aiko Medical also introduced the Lattice NEXT "no-extension guidewire" flow-directed stent, expanding its application to adult patients with unruptured saccular or fusiform wide-neck aneurysms in the internal carotid and vertebral arteries [2]. - The company has received NMPA approval for eight products, filed 132 patents, with 73 granted, and its Lattice stent has been recognized as an "innovative medical device" by the National Medical Products Administration [2]. - Aiko Medical aims to provide comprehensive innovative solutions for global cerebrovascular disease patients and doctors, focusing on domestic production and addressing unmet clinical needs in the cerebrovascular disease field [2].